Micro cap stocks 2019
At the beginning of 2019, the company announced its AXS-05 anti-depression and anti-smoking drug had managed to bypass the blood-brain barrier. Axsome’s current market cap is $3.4 billion. Its market cap was just $85 million at the beginning of 2019. It has gone from a tiny micro-cap stock to a multi-billion dollar enterprise in just one year. This is by far the best performing stock of 2019. Constellation Pharma has many other experimental drug candidates in its pipeline including the CPI-1205 and CPI-0209. The experimental drug aims to treat myelofibrosis.
Its share price jumped nearly 100% on November 6 when the company announced encouraging results of the Phase-2 clinical study for its experimental drug CPI-0610. This stock saw much of its gains in the last couple of months of 2019. 2- Constellation Pharmaceuticals Inc, +1,066% The department store chain sells off-price accessories, apparel, and footwear. But the stock is still far below its April 2013 high of $28.73 per share. Its upward rally began in September, ending the year at $8.2 per share. And the stock was nearly flat through August 2019. The Stage Stores stock had an interesting year. Later in December, JPMorgan initiated coverage of the stock with an Overweight rating and a price target of $82 per share. Kodiak’s drug candidate KSI-301 has shown promising results in clinical trials for the treatment of chronic retinal diseases. Advisors purchased 1.9 million shares of the biotech company, increasing their stake to slightly above 25%. Much of the gains came in December alone. Kodiak Sciences ended 2019 at $71.9 per share. In June 2019, its stock tripled after the company announced results of a study showing a single course of its PRV-031 drug delayed the onset of Type-1 diabetes even in high-risk individuals by more than two years. New Jersey-based Provention Bio is a clinical-stage biotech company engaged in the development of treatments for Type-1 diabetes and autoimmune diseases. Its stock began 2019 at $4.2 per share and ended the year above $34 a share. The Cambridge, Massachusetts-based company has tie-ups with leading insurers such as MetLife, Progressive, and others. EverQuote is an online insurance marketplace that connects consumers with relevant providers of auto, home, and life insurance. It’s one of the few non-biopharma companies on the list. In late December 2019, the US FDA approved its Investigational Device Exemption (IDE) application to conduct a feasibility study.
Micro cap stocks 2019 skin#
Avita Medical has developed a technology platform that enables repigmentation of depigmented skin associated with vitiligo. The stock was listed on Nasdaq on October 1, 2019. 7- Avita Medical, +719%Īvita Medical is a Perth, Australia-based regenerative medicine company.
Micro cap stocks 2019 trial#
Durect found that its DUR-928 drug did not benefit the clinical trial patients any more than placebo. Then the stock lost nearly 35% of its value on Januafter the company announced it would stop the development of a drug candidate for the treatment of psoriasis. Its stock was trading at just $0.5 per share at the beginning of 2019, but it ended the year at $3.8 a share. 8- Durect, +691%ĭurect is another biopharma company on the list. In late October, the IVERIC stock skyrocketed after the company announced positive clinical data for its eye drug avacincaptad pegol (Zimura). Its stock began 2019 at $1.2 per share and was nearly flat for most of the year. The biotech company focuses on the discovery and development of gene therapy solutions to treat orphan inherited retinal diseases. Nasdaq-listed IVERIC bio was previously known as Ophthotech Corporation.
In December 2019, pharma giant Merck reached a deal to buy ArQule for $20 per share, valuing it at $2.7 billion. On June 14, 2019, its shares shot up more than 50% when it announced the Phase-1 clinical trial data for its cancer drug candidate ARQ 531. The company has four clinical-stage drug candidates in pipeline. It’s engaged in research and development of drugs for cancer and rare diseases. ArQule is a biotech company founded in 1993.